Biotech Values

[biocqr]

ARWR > shows 3-6 month dosing possible using RNAi for dyslipidemias...

Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3

slide deck...http://ir.arrowheadpharma.com/static-files/ebe9c688-444c-43d4-97e6-bb4393652862

The data demonstrate that, in two Phase I single-dose clinical studies in healthy volunteers, ARO-APOC3 reduced plasma Apolipoprotein C-III (apoC-III) and ARO-ANG3 reduced plasma angiopoietin like protein 3 (ANGPTL3), and both candidates reduced triglycerides without drug-related serious or severe adverse events. These initial clinical data also indicate that ARO-APOC3 and ARO-ANG3 administration led to a long duration of effect that potentially enables once every three-month or once every six-month dosing intervals.

Top-line data from a single dose of 100 mg of ARO-APOC3 in healthy volunteers demonstrated mean maximal reductions of plasma triglycerides of 63% and APOC3 protein of 94% without serious or severe adverse events
The most common adverse events observed to date, all mild or moderate, have been headache, upper respiratory infection and mild injection site findings

Top-line data from a single dose of 200 mg of ARO-ANG3 in healthy volunteers demonstrated mean maximal reductions of plasma triglycerides of 66% and ANGPTL3 protein of 79% without drug-related serious or severe adverse events

The most common adverse events seen to date, all mild or moderate, have been headache and upper respiratory infection